Effects of a selective inhibitor of the Ab1 tyrosine kinase on the growth of Bcr-Ab1 positive cells

Nature Medicine

Volumn 2, Issue 5, 1996, Pages 561-566

  Druker, Brian J ^a   Tamura, Shu ^a   Buchdunger, Elisabeth ^b   Ohno, Sayuri ^a   Segal, Gerald M ^a   Fanning, Shake ^a   Zimmermann, Jürg ^b   Lydon, Nicholas B ^b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; PROTEIN KINASE; PROTEIN KINASE INHIBITOR;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; HUMAN; HUMAN CELL; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL;

ANIMALS; BLOOD CELLS; BONE MARROW; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; EVALUATION STUDIES; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOID, CHRONIC; MICE; PIPERAZINES; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-ABL; PYRIMIDINES; STEM CELLS; TUMOR CELLS, CULTURED;

EID: 0029947186     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm0596-561     Document Type: Article

References (52)

1. Kantarjian, H.M., Deisseroth, A.B., Kurzrock, R., Estrov, Z. & Talpaz, M. Chronic myelogenous leukemia: A concise update. Blood 82, 691-703 (1993).
2. Allan, N.C., Shepard, P.C.A. & Richards, R.M. Interferon alpha prolongs survival for patients with CML in chronic phase: Preliminary results of the UK MRC randomized multicenter trial. Blood 84, 382a (1994).
3. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N. Engl. J. Med. 330, 820-825 (1994).
4. Ozer, H. et al. Prolonged subcutaneous administration of recombinant alpha 2b interferon in patients with previously untreated Philadelphia chromosome-positive chronic-phase chronic myelogenous leukemia: Effect on remission duration and survival: Cancer and Leukemia Group B Study 8583. Blood 82, 2975-2984 (1993).
5. O'Brien, S.G. & Goldman, J.M. Autografting in chronic myeloid leukaemia. Blood Rev. 8, 63-69 (1994).
6. McGlave, P.B. et al. Autologous transplants for chronic myelogenous leukaemia: Results from eight transplant groups. Lancet 343, 1486-1488 (1994).
7. O'Brien, S.G. & Goldman, J.M. Current approaches to hematopoietic stem-cell purging in chronic myeloid leukemia. J. Clin. Oncol. 13, 541-546 (1995).
8. Nowell, P.C. & Hungerford, D.A. A minute chromosome in human chronic granulocytic leukemia. Science 132, 1497-1501 (1960).
9. Rowley, J.D. A new consistent abnormality in chronic myelogenous leukaemia identified by quinacrine, fluorescence and Giemsa staining. Nature 243, 290-293 (1973).
10. Heisterkamp, N. et al. Localization of the c-abl oncogene adjacent to a translocation break point in chronic myelocytic leukemia. Nature 306, 239-242 (1983).
11. Bartram, C.R. et al. Translocation of c-abl correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukemia. Nature 306, 277-280 (1983).
12. Shtivelman, E., Lifshitz, B., Gale, R.P. & Canaani, E. Fused transcript of abl and to genes in chronic myelogenous leukaemia. Nature 315, 550-554 (1985).
13. Clark, S.S. et al. Expression of a distinctive BCR-ABL oncogene in Ph1-positive acute lymphocytic leukemia (ALL). Science 239, 775-777 (1988).
14. Scott, M.L., Van Etten, R., Daley, G.Q. & Baltimore, D. v-abl causes hematopoietic disease distinct from that caused by bcr-abl. Proc. Natl. Acad. Sci. USA 88, 6506-6510 (1991).
15. Kelliher, M.A., McLaughlin, J., Witte, O.N. & Rosenberg, N. Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL. Proc. Natl. Acad. Sci. USA 87, 6649-6653 (1990).
16. Daley, G.Q., Van Etten, R.A. & Baltimore, D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 247, 824-830 (1990).
17. Oda, T., Tamura, S., Matsuguchi, T., Griffin, J.D. & Druker, B.J. The SH2 domain of Abl is not required for factor independent growth induced by Bcr-Abl in a murine myeloid cell line. Leukemia 9, 295-301 (1995).
18. Lugo, T.G., Pendergast, A.M., Muller, A.J. & Witte, O.N. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 247, 1079-1082 (1990).
19. Yaish, P., Gazit, A., Gilon, C. & Levitzki, A. Blocking of EGF-dependent cell proliferation by EGF receptor kinase inhibitors. Science 242, 933-935 (1988).
20. Levitzki, A. & Gazit, A. Tyrosine kinase inhibition: An approach to drug development. Science 267, 1782-1788 (1995).
21. Kaur, G. et al. Tyrphostin induced growth inhibition: Correlation with effect on p210bcr-abl autokinase activity in K562 chronic myelogenous leukemia. Anti-Cancer Drugs 5, 213-222 (1994).
22. bcr-ahltyrosine kinase activity induces K562 to differentiate. Blood 82, 3524-3529 (1993).
23. Furet, P. et al. Modeling study of protein kinase inhibitors - binding mode of staurosporine and origin of the selectivity of CGP 52411. J Comput. Aided Mol. Des. 9, 465-472 (1995).
24. Laneuviile, P., Heisterkamp, N. & Groffen, J. Expression of the chronic myel-ogenous leukemia-associated p210bcr/abl oncoprotein in a murine IL-3 dependent myeloid cell line. Oncogene 6, 275-282 (1991).
25. Matulonis, U., Salgia, R., Okuda, K., Druker, B. & Griffin, J.D. IL-3 and p210BCR/ABL activate both unique and overlapping pathways of signal transduction in a factor-dependent myeloid cell line. Exp. Hematol. 21, 1460-1466 (1993).
26. Daley, G.Q. & Baltimore, D. Transformation of an interleukin 3-dependent hematopoletic cell line by the chronic myelogenous leukemia-specific P210bcr/abl protein. Proc. Natl. Acad. Sci. USA 85, 9312-9316 (1988).
27. Honma, Y., Okabe, K.J., Hozumi, M., Uehara, Y. & Mizuno, S. Induction of erythroid differentiation of K562 human leukemic cells by herbimycin A, an inhibitor of tyrosine kinase activity. Cancer Res. 49, 331-4 (1989).
28. Schwartzberg, P.L. et al. Mice homozygous for the ablml mutation show poor viability and depletion of selected B and T cell populations. Cell 65, 1165-1175 (1991).
29. Sawyers, C.L., McLaughlin, J., Goga, A., Havlik, M. & Witte, O. The nuclear tyrosine kinase c-Abl negatively regulates cell growth. Cell 77, 121-131 (1994).
30. Silvennoinen, O. et al. Structure of the murine Jak2 protein-tyrosine kinase and its role in interleukin 3 signal transduction. Proc. Natl. Acad. Sci. USA 90, 8429-8433 (1993).
31. Caracciolo, D. et al. Lineage-specific requirement of c-abl function in normal hematopoiesis. Science 245, 1107-1110 (1989).
32. BCR-ABL expression and inhibit the proliferation of BCR/ABL-containing cell lines. Blood 81, 502-509 (1993).
33. Oda, T. et al. CRKL is the major tyrosine phosphorylated protein in neutrophils from patients with chronic myelogenous leukemia. J. Biol. Chem. 269, 22925-22928 (1994).
34. Evans, C.A., Owen-Lynch, P.J., Whetton, A.D. & Dive, C. Activation of the Abelson tyrosine kinase activity is associated with suppression of apoptosis in hemopoietic cells. Cancer Res. 53, 1735-1738 (1993).
35. Bedi, A., Zehnbauer, B.A., Barber, J.P., Sharkis, S.J. & Jones, R.J. Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia. Blood 83, 2038-2044 (1994).
36. Heldin, C.H. & Westermark, B. Platelet-derived growth factor: Mechanism of action and possible in vivo function. Cell Regul. 1, 555-566 (1990).
37. Kanakura, Y. et al. Signal transduction of the human granulocyte-macrophage colony-stimulating factor and interleukin-3 receptors involves a common set of cytoplasmic proteins. Blood 76, 706-715 (1990).
38. Greenberger, J.S., Sakakeeny, M.A., Humphries, R.K., Eaves, C.J. & Eckner, R.J. Demonstration of permanent factor-dependent multipotential (erythroid/neutrophil/basophil) hematopoietic progenitor cell lines. Proc. Natl. Acad. Sci. USA 80, 2391-2395 (1983).
39. Avanzi, G.C. et al. Selective growth response to IL-3 of a human leukaemic cell line with megakaryoblastic features. Br. J. Haematol. 69, 359-366 (1988).
40. Matsuguchi, T. et al. SHC phosphorylation in myeloid cells is regulated by GM-CSF, IL-3, and steel factor and is constitutively increased by p210BCR-ABL. J. Biol. Chem. 269, 5016-5021 (1994).
41. Erwin, J.L. & Anderson, S.M. Analysis of phosphotyrosine-containing proteins present in v-src-infected myeloid progenitor cells. Oncogene 7, 1101-1107 (1992).
42. Mossman, T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J. Immunol. Methods 65, 55-63 (1983).
43. Orkin, S.H., Harosi, F.I. & Leder, P. Differentiation in erythroleukemia cells and their somatic hybrids. Proc. Natl. Acad. Sci. USA 72, 98-102 (1975).
44. Buchdunger, E. et al. 4,5-Dianilinophthalimide: A protein-tyrosine kinase inhibitor with selectivity for the epidermal growth factor receptor signal transduction pathway and potent in vivo antitumor activity. Proc. Natl. Acad. Sci. USA 91, 2334-2338 (1994).
45. Buchdunger, E. et al. Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class. Proc. Natl. Acad. Sci. USA 92, 2558-2562 (1995).
46. Arion, D., Meijer, L., Brizuela, L. & Beach, D. cdc2 is a component of the M phase-specific histone H1 kinase: Evidence for identity with MPF. Cell 55, 371-378 (1988).
47. Pendergast, A.M. et al. Evidence for regulation of the human ABL tyrosine kinase by a cellular inhibitor. Proc. Natl. Acad. Sci. USA 88, 5927-5931 (1991).
48. Kharbanda, S. et al. Activation of the c-abl tyrosine kinase in stress response to DNA-damaging agents. Nature 376, 785-788 (1995).
49. Evans, B.D., Smith, I.E., Shorthouse, A.J. & Millar, J.L. A comparison of the response of human lung carcinoma xenografts to vindesine and vincristine. Br. J. Cancer. 45, 466-468 (1982).
50. Segal, G.M. et al. Repression of Fanconi anemia gene (FACC) expression inhibits growth of hematopoietic progenitor cells. J. Clin. Invest. 94, 846-852 (1994).
51. Hernandez, A. et al. Detection of the hybrid BCR/ABL messenger RNA in single CFU-GM colonies using the polymerase chain reaction. Exp. Hematol. 18, 1142-1144 (1990).
52. Dunn, O.J. Multiple comparisons using rank sums. Technometrics 6, 241-252 (1964).